Nicholas Investment Partners, LP Blueprint Medicines Corp Transaction History

Nicholas Investment Partners, LP

$845 Million
Q2 2024

A detailed history of Nicholas Investment Partners, LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Nicholas Investment Partners, LP holds 40,611 shares of BPMC stock, worth $3.75 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares

40,611

Holding current value

$3.75 Million

% of portfolio

0.52%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$85.18 - $108.78 $3.46 Million - $4.42 Million	40,611 New	40,611 $4.38 Million
Q3 2019 Nov 13, 2019	SELL	$72.9 - $101.41 $7.8 Million - $10.8 Million	-106,956 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$73.54 - $97.8 $2.39 Million - $3.18 Million	32,505 Added 43.66%	106,956 $10.1 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $3.63 Million - $6.45 Million	74,451 New	74,451 $5.96 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $2.23 Million - $3.63 Million	-48,921 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $25,979 - $34,539	-441 Reduced 0.89%	48,921 $3.82 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $902,573 - $1.5 Million	14,806 Added 42.85%	49,362 $3.13 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $234,422 - $329,337	-3,199 Reduced 8.47%	34,556 $3.17 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $22,710 - $31,883	361 Added 0.97%	37,755 $2.85 Million
Q3 2017 Nov 13, 2017	BUY	$42.37 - $69.67 $1.58 Million - $2.61 Million	37,394	37,394 $2.61 Million

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.52B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.

Account

Nicholas Investment Partners, LP Blueprint Medicines Corp Transaction History